Welcome to our dedicated page for Bicycle Therapeutics SEC filings (Ticker: BCYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hundreds of pages on peptide chemistry, Phase 1 dose-escalation results, and future funding needs make Bicycle Therapeutics� disclosures a challenge. Whether you are searching for Bicycle Therapeutics insider trading Form 4 transactions before a data read-out or trying to gauge cash runway in the next Bicycle Therapeutics quarterly earnings report 10-Q filing, the details are buried in dense biotech language.
Stock Titan solves that problem. Our AI decodes every submission on EDGAR, delivering Bicycle Therapeutics Form 4 insider transactions real-time and presenting Bicycle Therapeutics SEC filings explained simply—from clinical milestones to share-based compensation. You’ll receive concise Bicycle Therapeutics earnings report filing analysis, risk-factor highlights, and plain-English definitions so you can focus on decisions, not document hunting. It’s the fastest path to understanding Bicycle Therapeutics SEC documents with AI.
Need to track management’s confidence? Monitor Bicycle Therapeutics executive stock transactions Form 4. Curious about dilution or runway? Browse the Bicycle Therapeutics annual report 10-K simplified. Evaluating governance? Our platform links directly to the Bicycle Therapeutics proxy statement executive compensation. Material trial updates hit instantly too, with Bicycle Therapeutics 8-K material events explained in minutes. Every filing�10-K, 10-Q, 8-K, S-3, DEF 14A—lands here with AI-powered summaries, real-time alerts, and keyword search so you never miss a pipeline disclosure or funding move. Make informed calls faster, backed by complete, current information.
Bicycle Therapeutics plc filed a shelf registration to offer up to $500,000,000 of securities and included a resale prospectus covering 30,323,301 American Depositary Shares (ADSs) representing ordinary shares, of which 10,885,357 ordinary shares are presently issued and 19,437,944 ordinary shares may be redesignated from non-voting shares. The company’s ADSs trade on Nasdaq under the symbol BCYC with a most recent reported sale price of $8.05 per ADS.
Bicycle is a clinical-stage pharmaceutical company developing proprietary Bicycle4 molecules, short constrained peptides identified using a phage display screening platform that encodes quadrillions of candidates. The prospectus describes potential offerings of ordinary shares, ADSs, preference shares, debt, warrants, rights and units, confirms the company is a smaller reporting company, and notes this registration replaces a prior registration because the company is no longer a well-known seasoned issuer. The board has authority to allot shares up to a nominal 3,000,000 aggregate and preemptive rights were disapplied for a five-year period.
Bicycle Therapeutics plc (BCYC) reported Q2-25 results in its Form 10-Q. Collaboration revenue fell to $2.9 m (-69% YoY), reflecting timing of milestone receipts from Bayer, Novartis, Ionis and Genentech. Operating spend accelerated: R&D $71.0 m (+77%) as three clinical programs and the Duravelo-2 registrational trial ramped; G&A $18.5 m (+16%). Operating loss widened to $86.6 m; after $7.4 m of interest & other income, net loss was $79.0 m (-$1.14/sh), nearly double the prior-year quarter.
For the first six months, revenue dropped 56% to $12.9 m, while cumulative R&D rose 74% to $130.1 m. Six-month net loss reached $139.7 m (-$2.02/sh) and operating cash burn was $159.2 m.
Balance sheet strength remains the key offset. Cash & cash equivalents totaled $721.5 m (down $158 m YTD) following the $544 m May-24 private placement; management believes this funds operations for at least 12 months. Total liabilities are modest at $163.3 m; the $30 m Hercules term loan was fully repaid in July 2024, eliminating interest expense.
Share count at 8-5-25 was 49.9 m voting and 19.4 m non-voting shares, reflecting equity offerings and equity-based compensation.
Investment view: Ample cash provides runway to complete pivotal BT8009 trial, but the sharply rising R&D burn and highly dependent collaboration revenue increase execution risk and potential future dilution.
Bicycle Therapeutics plc filed a Form 8-K on 8 Aug 2025.
Item 2.02: The company furnished (not filed) a press release (Exhibit 99.1) containing financial results and business highlights for the quarter ended 30 Jun 2025. Actual revenue, EPS or cash-flow figures are not included in the 8-K; investors must refer to the exhibit for detail.
Item 5.02: The Board appointed Dr. Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP, as a Class II director and member of the Scientific Committee, effective 12 Aug 2025. Because he already chairs the Company’s Clinical Advisory Board, Nasdaq rules deem him non-independent. His term runs until the 2027 AGM. Compensation under the Non-Employee Director Policy: $50 k annual director cash, $10 k Scientific Committee cash, an option for 25,000 ordinary shares and 12,500 RSUs, each vesting in three equal annual instalments.
No other material transactions, financial statements or strategic updates are contained in the filing.
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
